Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study

医学 银屑病 内科学 银屑病面积及严重程度指数 生物标志物 随机对照试验 临床试验 胃肠病学 疾病 逻辑回归 皮肤病科 生物化学 化学
作者
Knut Schäkel,Kristian Reich,K. Asadullah,Andreas Pinter,D. Jullien,Peter Weisenseel,C. Paul,Mario Gomez,Sven Wegner,Yvonne Personke,Fabian Kreimendahl,Yanqing Chen,Julianty Angsana,Monica Leung,Kilian Eyerich
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:37 (10): 2016-2027 被引量:41
标识
DOI:10.1111/jdv.19236
摘要

Guselkumab is an interleukin (IL)-23 inhibitor with demonstrated efficacy in patients with psoriasis.Evaluate the impact of early disease intervention on clinical responses following 28 weeks of guselkumab treatment in patients with moderate-to-severe plaque psoriasis. Correlate clinical response and disease duration data with serum biomarker data.GUIDE is a phase IIIb randomized, double-blind, parallel-group, multicentre study of adults with moderate-to-severe plaque psoriasis. In study part 1, patients with a short disease duration (SDD [≤2 years]) or a long disease duration (LDD [>2 years]) received guselkumab 100 mg at Week (W) 0, 4, 12, and 20. Those achieving complete skin clearance at W20 and W28 were defined as a super responder (SRe). A multivariable logistic regression analysed the association between baseline factors and the likelihood of becoming an SRe. The relationship between clinical response, disease duration and serum biomarker data was assessed at W0 and 4.In total, 880 patients were enrolled (SDD/LDD = 40.6%/59.4% of patients). More SDD than LDD patients achieved absolute Psoriasis Area and Severity Index (PASI) = 0 at W28 (51.8% vs. 39.4%) and were SRes (43.7% vs. 28.1% [overall 34.4%]). SDD patients also achieved PASI = 0 quicker than LDD patients (median 141 vs. 200 days). Disease duration and prior biologic use had the greatest impact on becoming an SRe, with no strong association among these independent variables. At baseline, there were no significant differences in the serum biomarker levels of IL-17A, IL-17F, IL-22 and β-defensin 2 between SDD and LDD patients, or between SRe and non-SRe patients. Guselkumab rapidly decreased these markers of systemic inflammation across all patient groups analysed at W4. Guselkumab was well tolerated.Guselkumab efficacy was consistent across subpopulations, on the skin and systemically. The proportion of SRes was higher in SDD than LDD patients, indicating early treatment intervention may improve clinical outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
暴躁小龙发布了新的文献求助10
1秒前
张润泽完成签到 ,获得积分10
1秒前
2秒前
文档发布了新的文献求助10
2秒前
3秒前
5秒前
6秒前
6秒前
7秒前
8秒前
8秒前
烟花应助zwk采纳,获得10
10秒前
蔡芝艳关注了科研通微信公众号
10秒前
YI完成签到,获得积分10
13秒前
13秒前
大个应助科研通管家采纳,获得10
14秒前
14秒前
充电宝应助科研通管家采纳,获得10
15秒前
SYLH应助科研通管家采纳,获得20
15秒前
Ava应助科研通管家采纳,获得10
15秒前
丘比特应助科研通管家采纳,获得10
15秒前
情怀应助科研通管家采纳,获得10
15秒前
Hello应助科研通管家采纳,获得10
15秒前
Owen应助科研通管家采纳,获得10
15秒前
15秒前
su发布了新的文献求助10
17秒前
钟垠州完成签到 ,获得积分10
17秒前
17秒前
活力的妙之完成签到 ,获得积分10
17秒前
丘比特应助只想困瞌睡采纳,获得10
17秒前
小宋发布了新的文献求助10
18秒前
笃定发布了新的文献求助30
20秒前
淡墨完成签到,获得积分10
21秒前
今后应助清漪采纳,获得10
21秒前
zwk发布了新的文献求助10
22秒前
25秒前
鹿君浩发布了新的文献求助10
26秒前
26秒前
小宋完成签到,获得积分10
27秒前
呵呵哒完成签到,获得积分20
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158